Back to Studies
1077HS / HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)
HAART Standard Version of the PROMISE Study: Promoting Maternal and Infant Survival Everywhere
Participants Off Study and Primary Analysis Completed
Clinical Trials Link
Primary Protocol Team Members
1077HS is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). 1077HS is conducted among women who received highly active antiretroviral therapy (HAART) during pregnancy for purposes of prevention of mother-to-child transmission (PMTCT) of HIV but do not otherwise meet criteria to initiate HAART for their own health. The study is designed to determine whether continuation of HAART after delivery or other pregnancy outcome reduces morbidity and mortality compared to discontinuation and re-initiation of HAART according to current standards of care.
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...